Abstract
In 1959, future Nobel Laureate (1965) Dr. Richard Feynman presented a landmark lecture entitled “There’s Plenty of Room at the Bottom” to the American Physical Society where he postulated the miniaturization of science and challenged the audience: “How small can you make machinery?” Dr. Feynman’s early visions and conceptual thoughts of shrinking down our understanding of the physical realm and examining the elemental parts on a small scale was the earliest invitation for our exploration into the realm of nanotechnology [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Feynman RP. There's plenty of room at the bottom (data storage). J Microelectromech Syst. 1992;1(1):60–6.
Taniguchi N. On the basic concept of ‘Nano Technology’. Proceedings of the International Conference on Production Engineering, Tokyo, Part II (Japan Society of Precision Engineering). 1974.
Maddox MM, Liu J, Mandava SH, et al. Nanotechnology applications in urology: a review. Br J Urol. 2014;114:653–60.
Gommersall L, Shergill IS, Ahmed HU, et al. Nanotechnology and its relevance to the urologist. Eur Urol. 2007;52:368–75.
Chow EK, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med. 2013;5:216.
Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–9.
Feldman AS, McDougal WS, Harisinghani MG. The potential of nanoparticle-enhanced imaging. Urol Oncol. 2008;26:65–73.
Mirzaei M, Mehravi B, Ardestani MS, et al. In vitro evaluation of Gd(3+)−anionic linear globular dendrimer-monoclonal antibody: potential magnetic resonance imaging contrast agents for prostate cancer cell imaging. Mol Imaging Biol. 2015;17(6):770.
Shi C, Zhu Y, Cerwinka WH, et al. Quantum dots: emerging applications in urologic oncology. Urol Oncol. 2008;26:86–92.
Ma Q, Lin ZH, Yang N, et al. A novel carboxymethyl chitosan-quantum dot-based intracellular probe for ZN (2+) ion sensing in prostate cancer cells. Acta Biomater. 2014;10:868–74.
Fortier C, Dorucher Y, De Crecenzo G. Surface modification of nonviral nanocarriers for enhanced gene delivery. Nanomedicine. 2014;1:135–51.
Larchian WA, Horiguchi Y, Nair SK, et al. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Can Res. 2000;6:2913–20.
Hattori Y, Maitani Y. Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release. 2004;97:173–83.
Mofatt S, Papasakelariou C, et al. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. Gene Ther. 2006;13:761–72.
Mukherjee A, Darlington T, Baldwin R, et al. Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. ChemMedChem. 2014;19:1356–60.
Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57–64.
Barenholz Y. Doxil- the first FDA approved nano-drug: lessons learned. J Control Release. 2012;160:117–34.
Okada H, Doken Y, Ogawa Y, et al. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm Res. 1994;11:1143–7.
Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004;112:335–40.
Winquist E, Ernst DS, Jonker D, et al. Phase II trial of pegylated-liposomal doxorubicin in the treatment of advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract. Eur J Cancer. 2003;39:1866–71.
Sumitomo M, Koizumi F, Asano T, et al. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res. 2008;68:1631–5.
Liu J, Boonkaew B, Arora J, et al. Comparison of Sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticle in the in vitro treatment of renal cell carcinoma. J Pharm Sci. 2014;104:1187–96.
Kiyokawa H, Igawa Y, Mursahi O, et al. Distribution of doxorubicin in the bladder wall and regional lymph nodes after bladder submucosal injection of liposome doxorubicin in the dog. Urology. 1999;161:665–7.
Lu Z, Yeh TK, Tsai M, et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Can Res. 2004;10:7677–84.
Chen G, He Y, Wu X, et al. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer. Braz J Med Biol Res. 2012;45:771–6.
McKiernan JM, Holder DD, Ghandour RA, et al. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure. J Urol. 2014;192:1633–8.
Stern JM, Stanfield J, Lotan Y, et al. Efficacy of laser-activated gold nanoshells in ablating prostate cancer cells in vitro. J Endourol. 2007;8:939–43.
Stern JM, Stanfield J, Kabbani W, et al. Selective prostate cancer thermal ablation with laser activated gold nanoshells. J Urol. 2008;179:748–53.
Lee BR, Callaghan C, Mandava SH, et al. Nanotechnology combination therapy for renal cell carcinoma: gold nanorods bound with tyrosine kinase inhibitor produce synergistic treatment response when combined with laser thermal ablation in a renal cell carcinoma animal model. MP1–5, J Endo. 2015.
Kawai N, Ito A, Nakahara Y, et al. Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate. 2005;64:373–81.
Patil US, Adireddy S, Jaiswal A, et al. In vitro/in vivo toxicity evaluation and quantification of iron oxide nanoparticles. Int J Mol Sci. 2015;16:24417–50.
Fisher JW, Sarkar S, Buchanan CF, et al. Photothermal response of human and murine cancer cells to multiwalled carbon nanotubes after laser irradiation. Cancer Res. 2010;70:9855.
Burke A, Ding X, Singh R, et al. Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A. 2009;106:12897.
Humes HD. Bioartificial kidney for full renal replacement therapy. Semin Nephrol. 2000;20:71–82.
Nissenson AR, Ronco C, Pergamit G, et al. Continuously functioning artificial nephron system: the promise of nanotechnology. Hemodial Int. 2005;9:210–7.
Pattison MA, Wurster S, Webster TJ, et al. Three-dimensional, nanostructured PLGA scaffolds for bladder tissue replacement applications. Biomaterials. 2005;26:2491–500.
Roth CC. Urologic tissue engineering in pediatrics: from nanostructures to bladders. Pediatr Res. 2010;67:509–13.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Liu, J., Lee, B.R. (2018). Nanotechnology in Urology: History of Development and Applications in Urology. In: Patel, S., Moran, M., Nakada, S. (eds) The History of Technologic Advancements in Urology. Springer, Cham. https://doi.org/10.1007/978-3-319-61691-9_24
Download citation
DOI: https://doi.org/10.1007/978-3-319-61691-9_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-61689-6
Online ISBN: 978-3-319-61691-9
eBook Packages: MedicineMedicine (R0)